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Summary A proteinase accumulated in breast secretions from women with breast cancer has been charac-
terised. Inhibition of the proteolytic activity of breast secretions by pepstatin A showed that the main enzyme
involved was an aspartyl proteinase. Determination of its cleavage specificity by SDS-PAGE and amino acid
sequence analysis revealed that it was identical to that of cathepsin D, an aspartyl proteinase suggested to be
involved in breast cancer development. The identity between both proteins was further confirmed by
immunological analysis with monoclonal antibodies against cathepsin D. Quantification of cathepsin D in
nipple fluids from 41 women with benign or malignant breast diseases and from 19 control women without
breast pathology revealed the presence of variable amounts of this proteinase. The average concentration of
cathepsin D in breast secretions from cancer-bearing breasts was 7.2 ± 2.2 fmol fig of protein, which was
significantly higher than those of nipple fluids from control women (2.9 ± 0.6 fmoljigg') (P = 0.04) or from
patients with benign breast diseases (2.1 ± 0.3 fmol tg-') (P = 0.004). Though the number of cancer patients
studied was small (n = 21), no correlations were found with cytosolic concentrations of cathepsin D or
oestrogen receptors, neither with other parameters such as tumour size, histological grade, axillary node
involvement or menopausal status.
Over recent years, cytological and biochemical analyses of
secretions obtained from the nipple of nonlactating women
have been useful to assess the metabolic activity within the
mammary gland as well as to better understand the natural
history of breast cancer. Thus, cytological studies performed
by different groups (Sartorius et al., 1977; King et al., 1983;
Petrakis et al., 1987; Wrensch et al., 1992) have revealed the
presence of abnormal epithelial cells in breast fluids from
women with breast diseases, allowing the identification of
women who are at greater risk of developing breast cancer.
Similarly, biochemical analyses have demonstrated that these
fluids accumulate different substances which might be
involved in the tumour process. These products include hor-
mones (Miller et al., 1981; Hill et al., 1983; Rose, 1986),
mutagenic agents (Petrakis et al., 1980; Scott & Miller, 1990)
and toxic substances (Petrakis et al., 1978). In addition,
recent data from our laboratory indicate that breast secre-
tions can be subdivided into two types according to their
major polypeptide components. Type I secretions contain
distinctive proteins like apolipoprotein D, Zn-M2-glycoprotein
and gross cystic disease fluid protein-15 and are present in
most women without breast pathology or with benign breast
diseases. By contrast, Type II fluids, defined by the presence
of lactoferrin, lysozyme and a-lactalbumin, are present in
about 50% of women with breast cancer (Sa'nchez et al.,
1992b).
In the course of these studies on breast fluid composition,
it became apparent that some secretions and mainly those
obtained from patients with breast cancer contained pro-
teolytic activities of unknown nature. Since proteinases have
been proposed to play an important role in the developing of
tumour processes (Gottessman, 1990), studies were under-
taken to define the nature and properties of the putative
proteolytic enzymes present in breast secretions from women
with breast cancer. In this work we present evidence that
these fluids accumulate cathepsin D, an aspartyl proteinase
of potential importance in the malignant transformation of
mammary tissue and in breast cancer spread (Vignon et al.,
1986; Briozzo et al., 1988). We have also correlated the
values of cathepsin D in breast fluids with those determined
in tumour cytosols and with other clinical, histological and
biochemical parameters.
Materials and methods
Subjects
This study included 60 women ranged in age from 20 to 60
years who were examined at Hospital de Jove (Gijon, Spain).
There were 21 women with primary and unilateral breast
tumours, 20 women with benign breast diseases and 19 cont-
rol women. All cancers were infiltrating ductal carcinomas as
confirmed by biopsy. Histologic grade was determined ac-
cording to Bloom & Richardson, 1957. Most of them were
grade II tumours (14) but there were also grade I (4) and
grade III (3) carcinomas. The diagnosis of benign breast
diseases was based on clinical, mammographic, cytological
and echographic studies. Most women belonging to this
group were affected with fibrous mastopathy (18) but there
were also two patients affected with fibroadenoma. Control
women were volunteers from the family planning clinics or
from the general medical clinics. None of them had com-
plaints or significant clinical findings referrable to the breast.
Mean age and reproductive history of women from different
groups did not show significant differences. Women reporting
pregnancy or lactation at least 4 years prior to the study as
well as those who had been surgically treated during the
previous six months or were affected with endocrinological
pathology were excluded from the study.
Breastfluid collection
Breast secretions were obtained, with informed consent, by
manual compression of the nipple, collected with a capillary
tube and transferred into a microcentrifuge tube. In all cases,
nipple aspirates were obtained before any surgical procedure
on the breast. Fluids were typed according to their protein
pattern in SDS-polyacrylamide gel electrophoresis following
our previous classification (Satnchez et al., 1992b). Breast
secretions ranged in volume from 1 to 50 jd and their mean
protein concentration was 2.5i ggl-1'.
Tumour tissue extraction
After surgical excision, tumours were immediately frozen in
liquid nitrogen and stored at - 70°C until used. For the
biochemical determinations frozen tissues were pulverised
and homogenised at 4°C in 50 mM Tris pH 7.4 using a
Microdismembrator II (Braun-Melsungen, Germany). The
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homogenate was centrifuged at 105.000g for 1 h and the
resulting supernatants (cytosols) were collected and stored at
- 700C.
Cathepsin D immunoassay
Cathepsin D was determined in breast secretions and tumour
cytosols using a solid phase immunoradiometric assay
(ELSA-CathD kit, CIS BioInternational, Gif-sur-Yvette,
France). The assay involves two monoclonal antibodies, one
(D7E3) coated on the solid phase and the other (M1G8)
radiolabelled with 125I. In each ELSA tube 300,.l of 125I
monoclonal anticathepsin D and 50yl of each standard or
sample dilution were incubated for 3 h at room temperature
under agitation. After three washes, the radioactivity was
measured in a gamma scintillation counter LKB (Uppsala,
Sweden), model 1271. The assay was performed at different
dilutions (1:25, 1:100 and 1:250) to confirm the accuracy of
the cathepsin D measurements. In all cases there was
parallelism between standards and samples of breast secre-
tions. The sensitivity limit was about 0.2fmolpg` of total
protein in breast secretions.
Enzyme assays
Proteinase activity in breast secretions was determined by
incubating 1 jil of these fluids with 251il of 1% BSA in 0.1 M
sodium phosphate, pH 7.0 or pH 3.0. After 2 h at 370C,
aliquots of 1 ItI were removed, heated 5 min at 900C in SDS
reducing sample buffer and analysed by 12% SDS-
polyacrylamide gel electrophoresis. For inhibition assays, ali-
quots of 1 1tl of breast secretions were preincubated in 5 gl of
20mM sodium phosphate, pH 7.0 with different proteinase
inhibitors, including EDTA, PMSF, iodoacetic acid and
pepstatin A. After 1 h at room temperature, 20fsl of 1%
BSA in 0.1 M sodium phosphate, pH 3.0, were added. The
reaction mixture was incubated for 2 h at 37°C and analysed
by SDS-PAGE as indicated above.
Other biochemical assays
Protein concentration in breast secretions and tumour
cytosols was determined by the Bradford method (Bradford,
1976) using bovine gamma globulin as standard. Oestrogen
receptors were measured by enzyme-immunoassay using a
commercially available kit from Abbott Laboratories (North
Chicago, IL). Breast tumours were considered Oestrogen
receptor positive (ER +) if they contained more than
10 fmol mg-' of cytosolic protein.
Amino acidsequence analysis
Direct sequencing of protein fragments separated by SDS-
PAGE was accomplished according to the method of Mat-
sudaira (1987). Proteins were electrophoretically transferred
to a polyvinylidine fluoride membrane (PVDF) at 70 mA for
1 h in a Bio-Rad Trans Blot apparatus with a buffer contain-
ing 10 mM 3-(cyclohexylamino)-1-propanesulfonic acid, 4 mM
NaOH, and 10% (v/v) methanol. After staining with Coom-
assie blue, the membrane segment carrying the appropriate
protein fragment was placed directly into the reaction
chamber of an Applied Biosystems 477A automatic sequen-
cer. Edman degradation was performed according to the
program indicated by the manufacturer. The resulting
phenylthiohydantoin derivatives were identified and
quantified with an on-line phenylthiohydantoin analyser
(model 120A) and the standard Applied Biosystems program.
Statistical analysis
The analysis of differences was performed using Mann-
Whitney U test. Associations between variables were assessed
by the Spearman rank correlation test. Significance was
established at the P<0.05 level. Data were expressed as
mean ± s.e.m. and as medians.
Results
Preliminary characterisation ofproteolytic activities in breast
secretions
As a preliminary step to define the nature and properties of
proteolytic enzymes present in breast secretions, we examined
the ability of these fluids to degrade albumin and the results
obtained are shown in Figure 1. As can be seen, nipple
aspirates from both control and patients showed a very low
degrading activity on albumin at neutral pH (lanes b, c and
d). However, when these experiments were performed at pH
3.0 (lanes e, f and g), the fluids displayed a high level of
proteolytic activity. No enzymic activity was detected when
control samples without breast secretions were incubated
either at pH 7.0 or pH 3.0 (lane a), suggesting that the
observed degrading activity was due to the presence of breast
fluid proteinases. In addition, secretions obtained from
patients with breast cancer (lane g) appeared to show a
higher degrading activity when compared with those corres-
ponding to fluids from control women (lane e) or patients
with benign breast diseases (lane f). Analysis of the ability of
different proteinase inhibitors to abolish this enzymatic
activity revealed that pepstatin A displayed a strong
inhibitory effect (Figure 2). Since this inhibitor is very specific
against aspartic proteinases, these results indicated that the
enzyme responsible for the major proteolytic activity present
in breast secretions was an aspartyl-proteinase. It should be
also noted that EDTA displayed a partial inhibitory activity,
suggesting that additional enzymes such as metallop-
roteinases could be present in these breast fluids.
Taking into account the previous reports have indicated
that the aspartyl-proteinase cathepsin D is the predominant
proteinase secreted by breast cancer cells (Briozzo et al.,
1988), we examined the possibility that the major enzymatic
activity detected in breast secretions was due to this pro-
teinase. To do that, and since the minute amounts of breast
fluids which are usually available precluded the isolation of
the putative cathepsin D, we performed functional assays
with breast secretions by comparison of the cleavage
specificity of the aspartyl proteinase present in the fluids with
the corresponding one to purified cathepsin D. Thus, we
carried out limited proteolysis on albumin and determined
the NH2-terminal sequence of the predominant fragments
separated by SDS-PAGE. The results obtained are shown in
Figure 3. As can be seen, the pattern of fragments obtained
upon digestion with a breast secretion from a women with
breast cancer was identical to the one obtained with cathep-
sin D. In addition, amino acid sequencing allowed to confirm
the identity between the corresponding fragments obtained
from both sources (Figure 3). The pattern of fragments
obtained by using other proteolytic enzymes including pepsin
and cathepsin B was clearly distinct (data not shown).
Quantification ofcathepsin D in breast secretions
The above functional studies suggested that the aspartyl-
proteinase activity detected in breast secretions was due, at
least in part, to cathepsin D. To provide further insight on
this question, as well as to evaluate the possible clinical
significance of the presence of cathepsin D in breast secre-
tions, we undertook the quantification of this proteinase in
nipple aspirates obtained from control women without breast
pathologies and from patients with benign and malignant
breast diseases. Cathepsin D was measured by an
immunoradiometric assay in secretions from women belong-
ing to the different groups and the results obtained are shown
in Figure 4. The average concentration of this proteinase in
secretions from controls and from patients with benign
disease was very similar (2.9 ± 0.6 fmoljig-' of total protein
and 2.1 ± 0.3 fmol,tg-', respectively). By contrast, the levels
obtained in secretions from tumour-bearing breasts were
significantly higher (7.2 ± 2.2 fmol ig- '). In addition, this
value was also higher than the one obtained by measurement
of cathepsin D in fluids from contralateral breast of women1078 L.M. SANCHEZ et al.
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Figure 1 Digestion of bovine serum albumin by breast secretion proteinases. 25 iLl of 1% BSA in 0.1 M sodium phosphate, pH 7.0
or pH 3.0 were incubated with buffer (lane a) or with I jA of breast secretions from women without breast pathology (lanes b and
e), with benign breast disease (lanes c and f) or with breast carcinoma (lanes d and g). After 2 h at 37°C, aliquots of I tlI were
analysed by SDS-PAGE.
with cancer (3.6 ± 0.8 fmol ig-1). The corresponding
medians were 1.9 fmolfig-' in benign diseases, 1.7 fmolg.g-I
in controls, 4.4 fmolfig-' in tumour-bearing breasts and
2.7 fmolpg` in fluids from contralateral breasts. Taken
together, the obtained results appear to indicate that
accumulation of cathepsin D in breast secretions is
significantly associated with breast cancer (P<0.05, Mann-
Whitney U test), as determined by comparison of values in
aspirates from tumour bearing breasts to those from control
women or from patients with benign diseases. Finally it
should be mentioned that the failure to obtain secretions
from both breasts in a large number of patients with cancer
precluded the use of a paired test to further evaluate the
significance of differences between tumour-bearing breasts
and contralateral breasts.
Correlation between cathepsin D in breast secretions and other
clinical and biochemicalparameters
Cathepsin D concentration in breast tumour secretions were
first compared with the corresponding values of the enzyme
in breast tumour cytosols. Cathepsin D concentration in
these cytosols varied between 22.7 and 86.9 fmol Lg-' cytosol
protein with an average value of 44.8 ± 5.7 fmol j.g-'. Cor-
relation analysis showed that there was not any significant
relationship between the concentration determined in cytosols
and secretions (P = 0.56, r = -0.27). In addition, since
cathepsin D is an oestrogen-inducible protein in breast cancer
cells (Cavailles et al., 1988), we examined the possible
association between cathepsin D values in breast secretions
and ER concentration in the corresponding breast tumour
cytosols. Median values ofcathepsin D were not significantly
different in ER-positive than in ER-negative tumours
(4.6 fmol lg-' vs 4.6 fmol Lg-1 in the tumour breast and
2.4 fmolpg-' vs 1.3 fmol tLg-' in the contralateral breast).
Similarly, the concentrations of cathepsin D were not
significantly different in the two types of secretion defined on
the basis of their major protein components (medians;
5.6fmoltg-' in Type I and 4.1 fmolpg-' in Type II).
In order to establish the possible correlation between
cathepsin D values and disease status, clinical staging was
determined in the 21 women with breast cancer included in
the study and compared with cathepsin D concentrations. No
significant associations were found with any of the tumour or
patient characteristics investigated, including tumour size,
histological grade, menopausal status or axilliary node
involvement.
Discussion
In this work we have presented structural and functional
evidences indicating that the major proteolytic activity
detected in breast secretions corresponds to cathepsin D. In
addition, we show that accumulation of this proteinase in
mammary fluids is significantly associated with breast car-
cinoma.
The first purpose of this study was the identification of
proteolytic enzymes present in breast secretions. The finding
that an aspartyl-proteinase could account for a significant
part of the breast fluids proteolytic activity prompted us to
consider its possible relationship to cathepsin D, a lysosomal
aspartyl proteinase proposed to be involved in breast cancer
(Rochefort, 1990). The relationship between breast fluid pro-
teinase and cathepsin D was initially based on functional
findings since both enzymes displayed the same specificity as
judged by amino acid sequencing of the fragments produced
by their degrading activity on albumin. In addition,CATHEPSIN D IN BREAST SECRETIONS 1079
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Figure 2 Inhibition analysis of breast secretion proteinases. Aliquots of 1 1I of breast secretion from a women with breast cancer
were preincubated in 5A1 of 20 mm sodium phosphate, pH 7.0 with DMSO 20% (lane a), phosphate butter (lane b), 20 mM PMSF
in DMSO 20% (lane c), 0.5 g 1-' pepstatin A in DMSO 20% (lane d), 0.1 M EDTA (lane e), or 20 mM iodoacetic acid (lane f).
After 1 h at room temperature, the samples were mixed with 20p1 of 1% BSA in 0.1 M sodium phosphate, pH 3.0, incubated for
2 h at 37°C and analysed by SDS-PAGE.
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After these results indicating that cathepsin D is a major
proteinase in breast secretions, we tried to determine the
occurrence of possible differences in the levels of cathepsin D
in mammary fluids obtained from control women and from
patients with benign and malignant breast diseases. The
results obtained indicated that fluids from patients with
breast cancer showed significantly higher levels of cathepsin
D than those from control women and from patients with
benign breast diseases. In addition, cathepsin D levels in
fluids from contralateral breast of patients with breast cancer
were also lower than those from tumour-bearing breasts.
According to these data, it can be suggested that breast
epithelium and specially the one from patients with breast
cancer, has the ability to synthesise and secrete cathepsin D.
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Figure 3 Cleavage specificity on albumin of breast secretion
proteinases and cathepsin D. 25A1 of 1% BSA in 0.1 M sodium
phosphate, pH 3.0, were incubated with breast fluid from a
women with breast cancer (lane a) or with purified cathepsin D
(lane b). After 45 min at 37°C, samples were analysed by SDS-
PAGE, blotted to PVDF membranes and subjected to amino acid
sequence analysis. The sequences obtained in the major bands are
indicated by using the one-letter amino acid code (Maniatis et al.,
1982).
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immunological quantification performed with monoclonal
antibodies against cathepsin D allowed to confirm the
presence of a breast fluid protein recognised by these
antibodies.
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Figure 4 Distribution ofcathepsin D in breast secretions accord-
ing to breast pathology. Bars are median values.
35r1080 L.M. SANCHEZ et al.
This finding agrees well with in vitro results from Briozzo et
al. (1988), indicating that this enzyme is the predominant
proteinase secreted by breast cancer cells in culture medium.
In these breast cancer cells, cathepsin D is an oestrogen
induced protein, therefore it is possible that the finding of
elevated concentrations of this proteinase in breast secretions
can be a consequence of oestrogen stimulation of mammary
epithelium. However, since the mechanisms controlling
cathepsin D expression have not been yet elucidated, a possi-
ble role of additional stimuli or the existence of cooperative
interactions between different hormones or growth factors
should not be excluded.
Since cathepsin D values in breast tumour cytosol have
been proposed as a marker for predicting relapse-free sur-
vival in breast cancer patients (Spyratos et al., 1989; Thorpe
et al., 1989; Tandon et al., 1990; Duffy et al., 1991;
Rochefort, 1992), we tried to establish the possible correla-
tions between breast fluid and cytosol levels of this pro-
teinase. Although the limited number of cases in which both
values could be determined does not allow generalisation of
results, it became apparent that there was no correlation
between both parameters. According to this result, it can be
argued that breast fluid composition does not reflect
specifically the tumour metabolic activity within the mam-
mary gland. However, it should be considered that tumour
tissue homogenates used in the preparation of 'cytosol' frac-
tions contain a wide variety ofcellular components, including
inflammatory cells with ability of producing large amounts of
lysosomal enzymes as cathepsin D. Therefore, the specificity
of biochemical assays based on tumour extracts will be sub-
jected to the variable contribution of these non-tumour
cathepsin D producing cells (Henry et al., 1990).
At present, and due to the short follow-up of patients
whose breast fluid cathepsin D was measured, it is not possi-
ble to decide whether quantification of cathepsin D in breast
secretions could be of importance as a complementary
method to predict the clinical outcome of each particular
patient. Similarly, it is not possible to define the clinical
significance of the presence of high levels of cathepsin D in
some nipple aspirates obtained from women with benign
breast diseases or without breast pathologies. In relation to
this, it should be mentioned that on the basis of cathepsin D
measurements in breast cyst fluids, different laboratories
(Garcia et al., 1986, Scambia et al., 1991; S'anchez et al.,
1992a) have proposed that this proteinase is a potential
marker for distinguishing high-risk from low-risk benign
breast diseases. Further studies and long-term clinical follow-
up of the different subgroups of women, which are now in
progress, could be useful to define the actual prognostic value
of cathepsin D levels in breast secretions from women with
breast cancer. These studies will be also useful to evaluate the
possibility that accumulation of cathepsin D in these fluids
could reflect the existence of lesions at increased risk of
malignant transformation.
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